Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics.
Olagunju, A 1,2; Bolaji, O 2; Amara, A 3; Else, L 3; Okafor, O 4; Adejuyigbe, E 5; Oyigboja, J 6; Back, D 1; Khoo, S 1; Owen, A 1
[Article] Clinical Pharmacology & Therapeutics. 97(3):298-306, March 2015.

(Format: HTML, PDF)

: Pregnancy-induced physiological changes alter many drugs' pharmacokinetics. We investigated pregnancy-induced changes in efavirenz pharmacokinetics in 25 pregnant and 19 different postpartum women stratified from 211 HIV-positive women in whom a preliminary pharmacogenetic study had been undertaken. Despite significant changes in CL/F during pregnancy (42.6% increase; P = 0.023), median (range) Cmin was 1,000 ng/mL (429-5,190) with no significant change in Cmax (P = 0.072). However, when stratified for CYP2B6 516G>T (rs3745274) genotype, efavirenz AUC0-24, Cmax and Cmin were 50.6% (P = 0.0013), 17.2% (P = 0.14), and 61.6% (P = 0.0027) lower during pregnancy (n = 8) compared with postpartum (n = 6) in 516G homozygotes, with values of 25,900 ng.h/mL (21,700-32,600), 2,640 ng/mL (1,260-3,490), and 592 ng/mL (429-917), respectively, and CL/F was 100% higher (P = 0.0013). No changes were apparent in CYP2B6 516 heterozygotes (14 pregnant vs. 7 postpartum). The clinical implications of these findings warrant further investigation.

(C) Mosby-Year Book Inc. 2015. All Rights Reserved.